{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:11:29Z","timestamp":1790957489862,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2024MH29"],"award-info":[{"award-number":["ZR2024MH29"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jdiacomp.2025.109236","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:39:34Z","timestamp":1764117574000},"page":"109236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: A meta-analysis of over 30,000 patients"],"prefix":"10.1016","volume":"40","author":[{"given":"Qi","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfan","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2025.109236_bb0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","article-title":"Genetics of diabetes mellitus and diabetes complications","volume":"16","author":"Cole","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0010","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0015","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00125-010-1682-3","article-title":"Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis","volume":"53","author":"von Bibra","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0020","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2021.08.020","article-title":"Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults","volume":"78","author":"Segar","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/acssensors.1c02305","article-title":"Serum metal ion-induced cross-linking of photoelectrochemical peptides and circulating proteins for evaluating cardiac ischemia\/reperfusion","volume":"7","author":"Hao","year":"2022","journal-title":"ACS Sens"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0030","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/dom.15219","article-title":"Effects of once-weekly glucagon-like peptide-1 receptor agonists on type 2 diabetes mellitus complicated with coronary artery disease: potential role of the renin-angiotensin system","volume":"25","author":"Kan","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2174\/0115748863308106240816044733","article-title":"Long-term use of metformin and vitamin B12 deficiency in diabetes","volume":"20","author":"Hussain","year":"2025","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0040","article-title":"Innovation networks in the advanced medical equipment industry: supporting regional digital health systems from a local-national perspective","volume":"13","author":"Hu","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease \u2014 mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0050","series-title":"Cochrane","article-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","year":"2024"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0055","doi-asserted-by":"crossref","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0060","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/10641963.2016.1151526","article-title":"Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus","volume":"38","author":"Karashima","year":"2016","journal-title":"Clin Exp Hypertens"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0070","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0080","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0085","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ahj.2018.07.002","article-title":"A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: a randomized controlled double-blind trial","volume":"204","author":"Korol","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0090","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0095","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/HJH.0000000000003330","article-title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0100","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2020.08.005","article-title":"Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: data from the MIRAD trial","volume":"47","author":"Brandt-Jacobsen","year":"2021","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0110","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s13300-021-01118-7","article-title":"Effect of mineralocorticoid receptor antagonism and ACE inhibition on angiotensin profiles in diabetic kidney disease: an exploratory study","volume":"12","author":"Kovarik","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0115","doi-asserted-by":"crossref","first-page":"550","DOI":"10.5114\/aoms.2016.62448","article-title":"Effect of ramipril\/hydrochlorothiazide and ramipril\/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy","volume":"13","author":"Bosone","year":"2017","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0120","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria A randomized, double-blind, placebo-controlled, phase ii trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1463-1326.2007.00730.x","article-title":"Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS","volume":"10","author":"O\u2019Keefe","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0130","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0135","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0140","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2147\/DDDT.S151449","article-title":"A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients","volume":"12","author":"Derosa","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0145","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0150","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0155","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0160","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab105","article-title":"The role of the mineralocorticoid receptor and mineralocorticoid receptor\u2013directed therapies in heart failure","volume":"162","author":"Young","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0170","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","article-title":"Eplerenone: cardiovascular protection","volume":"107","author":"Brown","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jdiacomp.2025.109236_bb0175","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1586\/erc.12.64","article-title":"Eplerenone for the treatment of cardiovascular disorders","volume":"10","author":"Watanabe","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0180","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0185","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1161\/CIRCULATIONAHA.111.067918","article-title":"Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling","volume":"124","author":"Leopold","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0195","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/00325481.2022.2060598","article-title":"Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease","volume":"135","author":"Lerma","year":"2023","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0200","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/ehjcvp\/pvae049","article-title":"New ways of mitigating aldosterone in cardiorenal disease","volume":"10","author":"G\u00f6tzinger","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0210","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/00325481.2022.2060598","article-title":"Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease","volume":"135","author":"Lerma","year":"2023","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0215","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2174\/0113816128302667240422110226","article-title":"The regulation of selenoproteins in diabetes: a new way to treat diabetes","volume":"30","author":"Liang","year":"2024","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0220","article-title":"The signaling pathways of selected traditional Chinese medicine prescriptions and their metabolites in the treatment of diabetic cardiomyopathy: a review","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0225","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.56434\/j.arch.esp.urol.20247710.161","article-title":"Therapeutic efficacy of Re-Lin-Qing granules in treating type 2 diabetes mellitus complicated with urinary tract infection: a retrospective study","volume":"77","author":"Shan","year":"2024","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154887","article-title":"Quercetin: a promising therapy for diabetic encephalopathy through inhibition of hippocampal ferroptosis","volume":"126","author":"Cheng","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0235","first-page":"1","article-title":"Type 2 diabetes mellitus and the gut microbiota: charting new territory for sodium-glucose co-transporter 2 inhibitors","volume":"8","author":"Stepanova","year":"2024","journal-title":"Eurasian J Med Oncol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0240","doi-asserted-by":"crossref","first-page":"678","DOI":"10.24976\/Discov.Med.202436183.64","article-title":"Changes and significance of central carbon metabolism before and after metformin treatment of type 2 diabetes based on mass spectrometry","volume":"36","author":"Shu","year":"2024","journal-title":"Discov Med"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0245","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3923\/ijp.2023.100.113","article-title":"Antidiabetic activity of bacoside-A in nicotinamide-streptozotocin induced type 2 diabetes in rats","volume":"19","author":"Xue","year":"2023","journal-title":"Int J Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2018.12.016","article-title":"Cardioprotective actions of relaxin","volume":"487","author":"Martin","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/mgg3.1194","article-title":"The relaxin family peptide receptor 1 (RXFP1): an emerging player in human health and disease","volume":"8","author":"Chen","year":"2020","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108801","article-title":"From physiology to pathology: emerging roles of GPER in cardiovascular disease","volume":"267","author":"Wang","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114884","article-title":"Relaxin as an anti-fibrotic treatment: perspectives, challenges and future directions","volume":"197","author":"Samuel","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0270","first-page":"1367","article-title":"Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart","volume":"152","author":"Bani","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0275","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12974-020-01926-x","article-title":"Rh-relaxin-2 attenuates degranulation of mast cells by inhibiting NF-\u03baB through PI3K-AKT\/TNFAIP3 pathway in an experimental germinal matrix hemorrhage rat model","volume":"17","author":"Li","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0280","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00441-017-2662-4","article-title":"Alterations of relaxin and its receptor system components in experimental diabetic cardiomyopathy rats","volume":"370","author":"Zhang","year":"2017","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0285","doi-asserted-by":"crossref","first-page":"13767","DOI":"10.1080\/21655979.2022.2084253","article-title":"Based on network pharmacology and in vitro experiments to prove the effective inhibition of myocardial fibrosis by Buyang Huanwu decoction","volume":"13","author":"Wang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0290","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s10557-020-07072-z","article-title":"Rhodiola crenulata reduces ventricular arrhythmia through mitigating the activation of IL-17 and inhibiting the MAPK signaling pathway","volume":"35","author":"Hsiao","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2023.166726","article-title":"Inhibition of GSK3B phosphorylation improves glucose and lipid metabolism disorder","volume":"1869","author":"Yan","year":"2023","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0300","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41374-022-00819-2","article-title":"Hyperglycemia promotes myocardial dysfunction via the ERS-MAPK10 signaling pathway in db\/db mice","volume":"102","author":"Deng","year":"2022","journal-title":"Lab Invest"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0305","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/13880209.2022.2048029","article-title":"Berberine alleviates myocardial ischemia-reperfusion injury by inhibiting inflammatory response and oxidative stress: the key function of miR-26b-5p-mediated PTGS2\/MAPK signal transduction","volume":"60","author":"Jia","year":"2022","journal-title":"Pharm Biol"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0310","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2174\/0929866524666170728144357","article-title":"Renin-angiotensin system in diabetes","volume":"24","author":"Rein","year":"2017","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0315","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.diabres.2007.01.018","article-title":"Renin-angiotensin-system blockade in the prevention of diabetes","volume":"76","author":"Ostergren","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jdiacomp.2025.109236_bb0320","article-title":"Fibulin7 mediated pathological cardiac remodeling through EGFR binding and EGFR-dependent FAK\/AKT signaling activation","volume":"10","author":"Zheng","year":"2023","journal-title":"Adv Sci (Weinh)"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872725002892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T12:02:14Z","timestamp":1766232134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872725002892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1056872725002892"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109236","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: A meta-analysis of over 30,000 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109236"}}